Last reviewed · How we verify
AZD9550 and AZD6234 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AZD9550 and AZD6234 (AZD9550 and AZD6234) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AZD9550 and AZD6234 TARGET | AZD9550 and AZD6234 | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AZD9550 and AZD6234 CI watch — RSS
- AZD9550 and AZD6234 CI watch — Atom
- AZD9550 and AZD6234 CI watch — JSON
- AZD9550 and AZD6234 alone — RSS
Cite this brief
Drug Landscape (2026). AZD9550 and AZD6234 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd9550-and-azd6234. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab